Small molecule inhibitor of BCL2 in combination with RCHOP is effective in CD20 negative lymphoma

ABSTRACT: Rituximab alone or in combination with chemotherapeutics is the first-line therapy for variety of lymphoproliferative disorders including low- and high grade non-Hodgkin’s lymphomas (NHL). Although the complete response rate is quite impressive, vast majority of patient presents recurrent disease. The association between CD20 expression and clinical outcome in patients strongly suggests that reduced CD20 expression leads to inferior response to RCHOP (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone). In order to understand how loss of CD20 leads to development of RCHOP resistance, we developed rituximab resistant DOHH2 model in vivo by chronic exposure to rituximab. Characterization of several resistant in vivo xenografts revealed one model that maintained resistance t

ORGANISM(S): Homo sapiens

SUBMITTER: Zhongwu Lai 

PROVIDER: E-GEOD-54201 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress